BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Apoptosis
,
Influenza
,
Embryo
,
Early pregnancy factor
,
Lipitor
,
rs2230926
,
DRD2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
rilotumumab
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecita…
A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabi…
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clin…
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metas…
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus O…
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian T…
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Th…
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ